PubRank

Scott D Ramsey

Author PubWeight™ 125.21‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004 14.97
2 A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J Natl Cancer Inst 2010 4.04
3 Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol 2012 2.72
4 Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer 2006 2.42
5 A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med 2010 2.40
6 Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst 2014 2.30
7 Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm 2015 2.15
8 Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw 2012 2.13
9 Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013 2.11
10 Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res 2012 1.91
11 Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med 2014 1.87
12 Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J 2006 1.85
13 Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med 2007 1.77
14 Multi-modality mediastinal staging for lung cancer among medicare beneficiaries. J Thorac Oncol 2009 1.76
15 Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 2004 1.71
16 Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making 2013 1.70
17 The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2007 1.68
18 Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm 2015 1.67
19 The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics 2009 1.56
20 Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care 2007 1.38
21 Breast cancer in limited-resource countries: health care systems and public policy. Breast J 2006 1.35
22 Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. Genet Med 2012 1.32
23 Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care 2005 1.31
24 Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist 2010 1.30
25 Quantifying losses to the donated blood supply due to donor deferral and miscollection. Transfusion 2004 1.29
26 Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med 2005 1.27
27 Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care 2010 1.24
28 End-of-life care in the intensive care unit: can we simultaneously increase quality and reduce costs? Am J Respir Crit Care Med 2012 1.20
29 Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2009 1.17
30 Measuring costs: administrative claims data, clinical trials, and beyond. Med Care 2002 1.16
31 Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005 1.16
32 The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 2008 1.16
33 Physiologic variables and functional status independently predict COPD hospitalizations and emergency department visits in patients with severe COPD. COPD 2007 1.12
34 Does adherence make a difference? Results from a community-based aquatic exercise program. Nurs Res 2002 1.10
35 Economic analyses of human genetics services: a systematic review. Genet Med 2005 1.10
36 New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. J Am Geriatr Soc 2012 1.08
37 Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008 1.06
38 Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. Radiology 2014 1.05
39 Health technology assessment in health-care decisions in the United States. Value Health 2009 1.03
40 A multifaceted intervention in support of diabetes treatment guidelines: a cont trial. Diabetes Res Clin Pract 2002 1.02
41 Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer. J Oncol Pract 2013 1.01
42 Costs of pulmonary rehabilitation and predictors of adherence in the National Emphysema Treatment Trial. COPD 2008 1.00
43 Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J Natl Cancer Inst 2013 0.98
44 Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics 2010 0.98
45 Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int 2011 0.98
46 The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemp Clin Trials 2012 0.97
47 Improving early cycle economic evaluation of diagnostic technologies. Expert Rev Pharmacoecon Outcomes Res 2014 0.96
48 An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. J Gastroenterol Hepatol 2009 0.95
49 Community blood supply model: development of a new model to assess the safety, sufficiency, and cost of the blood supply. Med Decis Making 2005 0.94
50 Advanced diagnostic breast cancer imaging: variation and patterns of care in Washington state. J Oncol Pract 2013 0.93
51 Economic analyses and clinical practice guidelines: why not a match made in heaven? J Gen Intern Med 2002 0.93
52 Is distance to provider a barrier to care for medicaid patients with breast, colorectal, or lung cancer? J Rural Health 2011 0.93
53 Clinical use of medical devices in the 'Bermuda Triangle'. Health Aff (Millwood) 2004 0.92
54 Genetic services for familial cancer patients: a follow-up survey of National Cancer Institute Cancer Centers. J Clin Oncol 2005 0.92
55 Costs and outcomes evaluation of patient navigation after abnormal cancer screening: evidence from the Patient Navigation Research Program. Cancer 2013 0.92
56 Increased risk of adenomas in individuals with a family history of colorectal cancer: results of a meta-analysis. Cancer Causes Control 2010 0.92
57 Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs 2008 0.92
58 Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care 2004 0.91
59 Preference values associated with stage III colon cancer and adjuvant chemotherapy. Qual Life Res 2010 0.89
60 Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Epilepsia 2011 0.88
61 Systematic review of comparative effectiveness data for oncology orphan drugs. Am J Manag Care 2012 0.86
62 Completion of radiotherapy for local and regional head and neck cancer in medicare. Arch Otolaryngol Head Neck Surg 2009 0.86
63 The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer 2005 0.86
64 Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whites. Cancer 2010 0.85
65 Effect of radiotherapy interruptions on survival in medicare enrollees with local and regional head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010 0.85
66 Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. J Comp Eff Res 2012 0.84
67 Evidence-based management: using serial firm trials to improve diabetes care quality. Jt Comm J Qual Improv 2002 0.83
68 Screening for the Lynch syndrome. N Engl J Med 2005 0.83
69 Patient recruitment methods to evaluate treatment decision making for localized prostate cancer. Am J Clin Oncol 2010 0.82
70 Complementary and alternative medicine use among newly diagnosed prostate cancer patients. Support Care Cancer 2010 0.82
71 Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer. Oncologist 2014 0.82
72 Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases. Appl Health Econ Health Policy 2014 0.82
73 Promoting quality and evidence-based care in early-stage breast cancer follow-up. J Natl Cancer Inst 2014 0.82
74 The outcomes of the cancer outcomes research symposium: a commentary. Med Care 2002 0.81
75 Access to the Indian health service care system is not associated with early enrollment in medicaid for American Indian and Alaska Natives with cancer. Cancer Epidemiol Biomarkers Prev 2013 0.81
76 A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment. Pharmacoeconomics 2002 0.81
77 Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population. Int J Gen Med 2011 0.81
78 Health care use and primary prophylaxis with colony-stimulating factors. Value Health 2011 0.80
79 Moving beyond the national lung screening trial: discussing strategies for implementation of lung cancer screening programs. Oncologist 2013 0.80
80 How should we value lives lost to cancer? J Natl Cancer Inst 2008 0.79
81 Aspirin, clopidogrel, or both for secondary prevention of coronary disease. N Engl J Med 2003 0.79
82 Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective. Support Care Cancer 2013 0.79
83 Association of Preexisting Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. Patient 2008 0.79
84 Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2009 0.79
85 Body mass index and cancer screening in older American Indian and Alaska Native men. J Rural Health 2009 0.79
86 Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy use in nationally representative US claims database. BioDrugs 2014 0.78
87 Cost-effectiveness of prostate cancer chemoprevention among high-risk men. Expert Rev Pharmacoecon Outcomes Res 2010 0.78
88 Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research. Genet Med 2012 0.78
89 Lung cancer screening with low-dose computed tomography. J Natl Compr Canc Netw 2013 0.78
90 The forest and the trees: the human costs of cancer. J Natl Cancer Inst 2007 0.77
91 Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis. Value Health 2012 0.77
92 What Happens When Imatinib Goes Generic? J Natl Compr Canc Netw 2016 0.77
93 Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. J Comp Eff Res 2014 0.77
94 Cost effectiveness of a program to promote screening for cervical cancer in the Vietnamese-American population. Asian Pac J Cancer Prev 2010 0.77
95 Resource utilization, cost, and health status impacts of coronary stent versus "optimal" percutaneous coronary angioplasty: results from the OPUS-I trial. J Interv Cardiol 2002 0.77
96 Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. J Comp Eff Res 2013 0.77
97 Illness-associated productivity costs among women with employer-sponsored insurance and newly diagnosed breast cancer. J Occup Environ Med 2010 0.76
98 Performance goals for an adjunct diagnostic test to reduce unnecessary biopsies after screening mammography: analysis of costs, benefits, and consequences. J Am Coll Radiol 2013 0.76
99 The Authors Respond. J Manag Care Spec Pharm 2015 0.75
100 Economics and the new generation of targeted therapies for non-small cell lung cancer. J Natl Cancer Inst 2010 0.75
101 Comparative effectiveness of robotically assisted compared with laparoscopic adnexal surgery for benign gynecologic disease. Obstet Gynecol 2014 0.75
102 Coronary artery bypass grafting in octogenarians: clinical and economic outcomes at community-based healthcare facilities. Am J Manag Care 2002 0.75
103 Cancer Treatment Delays in American Indians and Alaska Natives Enrolled in Medicare. J Health Care Poor Underserved 2017 0.75
104 Proof or principle? On economic modeling to guide genomic testing in metastatic colorectal cancer. J Natl Cancer Inst 2012 0.75